Guggenheim analyst William Tanner named Novavax (NASDAQ: NVAX) its Best Idea and reiterated a Buy rating and price target of ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments FDA Hot Comments